Cranbury Forms From Tris Pharma, With First Generic DMD Treatment Deflazacort
Tris Pharma’s Jannet Penner Named As Cranbury’s President; 20 Generics Marketed
Tris Pharma has handed over the keys to its generics portfolio and pipeline to a new subsidiary, Cranbury Pharmaceuticals, which has debuted competition to PTC Therapeutics’ Emflaza (deflazacort) oral suspension.
